Physician profile
James D Relle
NPI 1215919048
$6,886.58
in general payments reported to CMS, 2019-2025
46 companies · $1,901 in 2025
The $1,901 reported for 2025 was more than what 79% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $270 · 2021: $327 · 2022: $718 · 2023: $1,014 · 2024: $1,475 · 2025: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,000 · Consulting Fee: $355 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,999.59 |
| Consulting Fee | $355.00 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $643.21 | 2024-2025 | Nuro, Interstim |
| Ferring Pharmaceuticals INC. | $470.80 | 2019-2025 | Adstiladrin |
| Teleflex LLC | $465.55 | 2021-2025 | Urolift |
| Sumitomo Pharma America, INC. | $458.83 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $410.45 | 2019-2025 | Xtandi, Myrbetriq |
| Medtronic USA, INC. | $348.04 | 2019-2020 | |
| Urogen Pharma, INC. | $259.58 | 2023-2025 | Jelmyto |
| Antares Pharma, INC. | $257.80 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $238.32 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $237.33 | 2019-2025 | Provenge |
| Olympus America INC. | $229.14 | 2021-2025 | Itind System |
| Axonics, INC. | $215.34 | 2022-2024 | Axonics |
| Myriad Genetic Laboratories, INC. | $193.21 | 2023-2025 | Prolaris, Myrisk |
| Boston Scientific Corporation | $185.45 | 2019-2025 | Axonics, Ams 700, Solyx Sis System |
| Tolmar, INC. | $177.97 | 2023-2025 | Eligard, Jatenzo |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $173.01 | 2025 | |
| Janssen Biotech, INC. | $145.80 | 2023-2025 | Erleada, Akeega |
| Astrazeneca Pharmaceuticals LP | $130.25 | 2021-2025 | Lynparza, Imfinzi |
| Coloplast Corp | $127.88 | 2019-2024 | Speedicath, Saffron |
| Laborie Medical Technologies Corp. | $121.13 | 2023-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Merck Sharp & Dohme LLC | $117.39 | 2022-2025 | Lynparza, Keytruda |
| Abbvie INC. | $113.19 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.12 | 2019-2025 | |
| Photocure INC | $96.80 | 2023-2025 | Cysview |
| Amgen INC. | $92.39 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $81.76 | 2019-2023 | Xiaflex |
| Immunitybio, INC. | $80.82 | 2024-2025 | |
| Procept Biorobotics Corporation | $76.80 | 2020-2023 | Aquabeam Robotic System |
| Urovant Sciences INC | $73.12 | 2021-2022 | |
| Blue Earth Diagnostics | $60.13 | 2019-2025 | Posluma |
| Endo USA, INC. | $58.12 | 2025 | Xiaflex, Aveed |
| Neotract INC. | $55.09 | 2019-2020 | |
| Halozyme INC | $46.15 | 2023 | |
| Calyxo, INC. | $42.11 | 2024-2025 | Cvac Aspiration System |
| Clarus Therapeutics INC. | $38.52 | 2021 | |
| Allergan, INC. | $34.20 | 2021 | |
| 180 Medical, INC. | $32.37 | 2023 | |
| Progenics Pharmaceuticals, INC. | $28.09 | 2022 | |
| Verity Pharmaceuticals INC. | $27.19 | 2025 | Tlando |
| Tempus Ai, INC | $25.09 | 2024 | |
| Ambu INC. | $24.65 | 2023 | |
| C. R. Bard, INC. & Subsidiaries | $22.69 | 2025 | Bard Urinary Drainage Bag |
| Integra Lifesciences Corporation | $22.21 | 2024 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Novartis Pharmaceuticals Corporation | $17.00 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $15.37 | 2019 | |
| Therapeuticsmd, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Relle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.